Q2 FY2026 · Press release
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) · 4 pages
Read Ultragenyx Pharmaceutical Inc.'s results firsthand
Preview the first 2 pages of this press release
Create a free account to start reading
Full documents are included with Professional
